YOKOHAMA, Japan, March 16, 2022–(Organization WIRE)–CoreTissue BioEngineering Inc., a health care device firm producing an synthetic ligament derived from decellularized animal tissue, was approved into Johnson & Johnson Innovation – JPOD @ Boston.
CoreTissue BioEngineering will develop its footprint and speed up company progress in the US via its aid crew and choose essential belief leaders (KOLs).
About CoreTissue BioEngineering Inc.
Dependent in Yokohama, Japan, CoreTissue BioEngineering, Inc. is a spinout firm from Waseda University in Japan. We come to feel our staff of Harvard-qualified biomedical scientist, seasoned senior management in professional medical product improvement, and experienced scientific research specialist has the suitable abilities to carry this mission to possible achievement.
Following our results in establishing synthetic ligament for ACL reconstruction medical procedures, we program to even further use our technological innovation platform to the enhancement of health-related units for the broader human musculoskeletal procedure.
CoreTissue BioEngineering has by now validated a evidence-of-principle of the merchandise in an ovine large animal analyze with a prototype produced making use of these systems. The firm has acquired sturdy backing from the Japanese governing administration, the Japan Agency for Health care Research and Enhancement (AMED) for development from early feasibility by way of pivotal trial.
For additional data, stop by https://www.coretissue.com/?lang=en
Check out resource edition on businesswire.com: https://www.businesswire.com/information/dwelling/20220302006183/en/
CoreTissue BioEngineering Inc.
E-mail: [email protected]